Abeona Therapeutics (ABEO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

ABEO Stock Forecast

Abeona Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 5.26% upside from ABEO’s last price of $5.70) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ABEO Price Target

The average price target for Abeona Therapeutics (ABEO) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 5.26% upside from ABEO's last price of $5.70.

ABEO Analyst Ratings

Buy

According to 3 Wall Street analysts, Abeona Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ABEO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Abeona Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 14, 2022		Leerink Partners	$6.00	$4.15	44.58%	5.26%

The latest Abeona Therapeutics stock forecast, released on Nov 14, 2022 by Leerink Partners company, set a price target of $6.00, which represents a 44.58% increase from the stock price at the time of the forecast ($4.15), and a 5.26% increase from ABEO last price ($5.70).

Abeona Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$5.70	$5.70	$5.70
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Abeona Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Abeona Therapeutics's last price of $5.70. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 03, 2024	H.C. Wainwright		Buy	Initialise
May 16, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Nov 14, 2022	SVB Leerink	Market Perform	Market Perform	Hold

Abeona Therapeutics's last stock rating was published by H.C. Wainwright on Jul 03, 2024. The company Initialise its ABEO rating from "null" to "Buy".

Abeona Therapeutics Financial Forecast

Abeona Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 22	Mar 22	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Jun 15	Mar 12	Mar 11	Jun 10	Sep 09	Jun 08	Jun 02
Revenue	-	-	-	-	-	-	-	-	$68.00K	$346.00K	$3.00M	$7.00M	-	-	-	$2.60M	$186.00K	$235.00K	$282.00K	$1.85M	$150.00K	$105.00K	$144.00K	-	-
Avg Forecast	$13.93M	$4.25M	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$166.67K	$1.00M	$253.73K	$5.37M	$1.40M	$120.00K	$300.00K	$778.50K	$559.44K	$219.23K	$183.53K	$232.65K	$2.58M	$160.71K	$172.86K	$87.03K	$118.53K	$216.67K
High Forecast	$13.93M	$4.25M	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$166.83K	$1.00M	$304.48K	$5.37M	$1.40M	$120.00K	$300.00K	$778.50K	$671.33K	$263.07K	$220.23K	$279.18K	$3.09M	$192.86K	$207.43K	$104.43K	$142.24K	$260.00K
Low Forecast	$13.93M	$4.25M	$125.00K	$125.00K	$100.00K	$100.00K	$100.00K	$166.50K	$1.00M	$202.99K	$5.37M	$1.40M	$120.00K	$300.00K	$778.50K	$447.55K	$175.38K	$146.82K	$186.12K	$2.06M	$128.57K	$138.28K	$69.62K	$94.82K	$173.33K
# Analysts	1	1	1	4	6	3	3	3	4	17	10	16	8	10	16	18	20	19	10	14	10	15	10	11	8
Surprise %	-	-	-	-	-	-	-	-	0.07%	1.36%	0.56%	5.00%	-	-	-	4.64%	0.85%	1.28%	1.21%	0.72%	0.93%	0.61%	1.65%	-	-

Abeona Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $166.67K, with a low forecast of $166.50K, and a high forecast of $166.83K. ABEO's average Quarter revenue forecast represents a 145.10% increase compared to the company's last Quarter revenue of $68.00K (Dec 22).

Abeona Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 22	Mar 22	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Jun 15	Mar 12	Mar 11	Jun 10	Sep 09	Jun 08	Jun 02
# Analysts	1	1	1	4	6	3	3	3	4	17	10	16	8	10	16	18	20	19	10	14	10	15	10	11	8
EBITDA	-	-	-	-	-	-	-	-	$-10.37M	$-13.31M	$-13.34M	$-4.81M	$-15.34M	$-21.87M	$-16.90M	$-8.29M	$-5.00M	$-5.37M	$-3.98M	$-4.67M	$-1.67M	$1.99M	$-3.87M	-	-
Avg Forecast	$-8.36M	$-2.55M	$-75.00K	$-75.00K	$-60.00K	$-60.00K	$-60.00K	$-100.00K	$-600.00K	$-9.52M	$-3.22M	$-840.00K	$-72.00K	$-180.00K	$-13.20M	$-8.72M	$-5.66M	$-3.72M	$-3.13M	$-11.41M	$-1.78M	$-103.71K	$-1.67M	$-1.83M	$-1.46M
High Forecast	$-8.36M	$-2.55M	$-75.00K	$-75.00K	$-60.00K	$-60.00K	$-60.00K	$-99.90K	$-600.00K	$-7.62M	$-3.22M	$-840.00K	$-72.00K	$-180.00K	$-10.56M	$-6.98M	$-4.53M	$-2.97M	$-2.51M	$-9.12M	$-1.43M	$-82.97K	$-1.33M	$-1.46M	$-1.17M
Low Forecast	$-8.36M	$-2.55M	$-75.00K	$-75.00K	$-60.00K	$-60.00K	$-60.00K	$-100.10K	$-600.00K	$-11.43M	$-3.22M	$-840.00K	$-72.00K	$-180.00K	$-15.84M	$-10.47M	$-6.79M	$-4.46M	$-3.76M	$-13.69M	$-2.14M	$-124.46K	$-2.00M	$-2.19M	$-1.75M
Surprise %	-	-	-	-	-	-	-	-	17.29%	1.40%	4.14%	5.72%	213.06%	121.48%	1.28%	0.95%	0.88%	1.44%	1.27%	0.41%	0.94%	-19.21%	2.32%	-	-

10 analysts predict ABEO's average Quarter EBITDA for Mar 11 to be $-1.78M, with a high of $-1.43M and a low of $-2.14M. This is -189.48% lower than Abeona Therapeutics's previous annual EBITDA (Jun 10) of $1.99M.

Abeona Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 22	Mar 22	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Jun 15	Mar 12	Mar 11	Jun 10	Sep 09	Jun 08	Jun 02
# Analysts	1	1	1	4	6	3	3	3	4	17	10	16	8	10	16	18	20	19	10	14	10	15	10	11	8
Net Income	-	-	-	-	-	-	-	-	$6.42M	$-20.99M	$-15.83M	$-7.24M	$-17.37M	$-23.92M	$-18.55M	$-8.46M	$-5.25M	$-5.54M	$-4.11M	$-4.89M	$-1.90M	$1.79M	$-4.07M	-	-
Avg Forecast	$-6.41M	$-14.91M	$-17.79M	$-17.15M	$-16.54M	$-18.87M	$-16.44M	$-24.68M	$-36.06M	$-10.16M	$-128.07M	$-183.56M	$-558.01M	$-467.53M	$-14.50M	$-8.91M	$-5.95M	$-3.84M	$-3.24M	$-11.95M	$-2.03M	$2.44M	$-1.75M	$-1.99M	$-1.85M
High Forecast	$-6.41M	$-14.91M	$-17.79M	$-17.15M	$-15.12M	$-18.87M	$-16.44M	$-24.68M	$-36.06M	$-8.13M	$-128.07M	$-183.56M	$-558.01M	$-467.53M	$-11.60M	$-7.13M	$-4.76M	$-3.07M	$-2.59M	$-9.56M	$-1.62M	$2.93M	$-1.40M	$-1.59M	$-1.48M
Low Forecast	$-6.41M	$-14.91M	$-17.79M	$-17.15M	$-18.43M	$-18.87M	$-16.44M	$-24.68M	$-36.06M	$-12.20M	$-128.07M	$-183.56M	$-558.01M	$-467.53M	$-17.40M	$-10.69M	$-7.14M	$-4.61M	$-3.89M	$-14.34M	$-2.43M	$1.95M	$-2.10M	$-2.39M	$-2.22M
Surprise %	-	-	-	-	-	-	-	-	-0.18%	2.07%	0.12%	0.04%	0.03%	0.05%	1.28%	0.95%	0.88%	1.44%	1.27%	0.41%	0.94%	0.73%	2.32%	-	-

Abeona Therapeutics's average Quarter net income forecast for Mar 24 is $-24.68M, with a range of $-24.68M to $-24.68M. ABEO's average Quarter net income forecast represents a -484.75% decrease compared to the company's last Quarter net income of $6.42M (Dec 22).

Abeona Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 22	Mar 22	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Jun 15	Mar 12	Mar 11	Jun 10	Sep 09	Jun 08	Jun 02
# Analysts	1	1	1	4	6	3	3	3	4	17	10	16	8	10	16	18	20	19	10	14	10	15	10	11	8
SG&A	-	-	-	-	-	-	-	-	$5.68M	$4.22M	$7.40M	$4.43M	$4.70M	$5.61M	$5.66M	$2.88M	$3.02M	$4.37M	$3.67M	$979.00K	$1.03M	$1.25M	$3.46M	-	-
Avg Forecast	$79.68M	$24.32M	$715.24K	$715.24K	$572.19K	$572.19K	$572.19K	$953.66K	$5.72M	$1.43M	$30.22M	$7.88M	$675.71K	$1.69M	$4.38M	$3.15M	$1.23M	$1.03M	$1.31M	$2.39M	$904.96K	$973.34K	$490.04K	$667.43K	$1.22M
High Forecast	$79.68M	$24.32M	$715.24K	$715.24K	$572.19K	$572.19K	$572.19K	$954.61K	$5.72M	$1.71M	$30.22M	$7.88M	$675.71K	$1.69M	$4.38M	$3.78M	$1.48M	$1.24M	$1.57M	$2.87M	$1.09M	$1.17M	$588.04K	$800.91K	$1.46M
Low Forecast	$79.68M	$24.32M	$715.24K	$715.24K	$572.19K	$572.19K	$572.19K	$952.70K	$5.72M	$1.14M	$30.22M	$7.88M	$675.71K	$1.69M	$4.38M	$2.52M	$987.56K	$826.74K	$1.05M	$1.91M	$723.96K	$778.66K	$392.02K	$533.94K	$976.01K
Surprise %	-	-	-	-	-	-	-	-	0.99%	2.96%	0.24%	0.56%	6.96%	3.32%	1.29%	0.91%	2.45%	4.22%	2.80%	0.41%	1.13%	1.29%	7.06%	-	-

Abeona Therapeutics's average Quarter SG&A projection for Mar 24 is $953.66K, based on 3 Wall Street analysts, with a range of $952.70K to $954.61K. The forecast indicates a -83.22% fall compared to ABEO last annual SG&A of $5.68M (Dec 22).

Abeona Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 22	Mar 22	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Jun 15	Mar 12	Mar 11	Jun 10	Sep 09	Jun 08	Jun 02
# Analysts	1	1	1	4	6	3	3	3	4	17	10	16	8	10	16	18	20	19	10	14	10	15	10	11	8
EPS	-	-	-	-	-	-	-	-	$0.82	$-3.62	$-4.26	$-1.93	$-8.73	$-12.22	$-9.67	$-4.50	$-3.26	$-4.23	$-4.00	$-253.26	$-123.37	$80.09	$-416.95	-	-
Avg Forecast	$-0.13	$-0.31	$-0.37	$-0.36	$-0.34	$-0.39	$-0.34	$-0.51	$-0.75	$-2.38	$-2.50	$-3.58	$-10.89	$-9.13	$-7.95	$-5.00	$-4.25	$-2.25	$-1.77	$213.75	$-200.00	$-187.50	$-123.75	$-487.50	$-750.00
High Forecast	$-0.13	$-0.31	$-0.37	$-0.36	$-0.31	$-0.39	$-0.34	$-0.51	$-0.75	$-2.38	$-2.50	$-3.58	$-10.89	$-9.13	$-7.95	$-4.00	$-3.40	$-1.80	$-1.42	$256.50	$-160.00	$-150.00	$-99.00	$-390.00	$-600.00
Low Forecast	$-0.13	$-0.31	$-0.37	$-0.36	$-0.38	$-0.39	$-0.34	$-0.51	$-0.75	$-2.38	$-2.50	$-3.58	$-10.89	$-9.13	$-7.95	$-6.00	$-5.10	$-2.70	$-2.13	$171.00	$-240.00	$-225.00	$-148.50	$-585.00	$-900.00
Surprise %	-	-	-	-	-	-	-	-	-1.09%	1.52%	1.70%	0.54%	0.80%	1.34%	1.22%	0.90%	0.77%	1.88%	2.26%	-1.18%	0.62%	-0.43%	3.37%	-	-

According to 3 Wall Street analysts, Abeona Therapeutics's projected average Quarter EPS for Mar 24 is $-0.51, with a low estimate of $-0.51 and a high estimate of $-0.51. This represents a -162.60% decrease compared to ABEO previous annual EPS of $0.82 (Dec 22).

Abeona Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ATHA	Athira Pharma	$0.59	$18.00	2950.85%	Buy
IVVD	Invivyd	$0.49	$9.50	1838.78%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
ADAP	Adaptimmune Therapeutics	$0.60	$4.00	566.67%	Buy
CABA	Cabaletta Bio	$2.75	$16.33	493.82%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
CKPT	Checkpoint Therapeutics	$3.72	$20.00	437.63%	Buy
AFMD	Affimed	$1.51	$7.50	396.69%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
RGNX	REGENXBIO	$8.47	$29.75	251.24%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
LPTX	Leap Therapeutics	$3.11	$5.50	76.85%	Buy
ACAD	ACADIA Pharmaceuticals	$17.41	$25.50	46.47%	Buy
ABEO	Abeona Therapeutics	$5.88	$6.00	2.04%	Buy

ABEO Forecast FAQ

Is Abeona Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Abeona Therapeutics (ABEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ABEO's total ratings.

What is ABEO's price target?

Abeona Therapeutics (ABEO) average price target is $6 with a range of $6 to $6, implying a 5.26% from its last price of $5.7. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Abeona Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ABEO stock, the company can go up by 5.26% (from the last price of $5.7 to the average price target of $6), up by 5.26% based on the highest stock price target, and up by 5.26% based on the lowest stock price target.

Can Abeona Therapeutics stock reach $9?

ABEO's average twelve months analyst stock price target of $6 does not support the claim that Abeona Therapeutics can reach $9 in the near future.

What are Abeona Therapeutics's analysts' financial forecasts?

Abeona Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $466.67K (high $466.83K, low $466.5K), average EBITDA is $-280K (high $-280K, low $-280K), average net income is $-76.538M (high $-75.12M, low $-78.428M), average SG&A $2.67M (high $2.67M, low $2.67M), and average EPS is $-1.592 (high $-1.562, low $-1.631). ABEO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $18.42M (high $18.42M, low $18.42M), average EBITDA is $-11.055M (high $-11.055M, low $-11.055M), average net income is $-56.256M (high $-56.256M, low $-56.256M), average SG&A $105.43M (high $105.43M, low $105.43M), and average EPS is $-1.17 (high $-1.17, low $-1.17).

Did the ABEO's actual financial results beat the analysts' financial forecasts?

Based on Abeona Therapeutics's last annual report (Dec 2022), the company's revenue was $1.41M, beating the average analysts forecast of $1.25M by 12.78%. Apple's EBITDA was $-44.685M, beating the average prediction of $-10.122M by 341.46%. The company's net income was $-31.809M, missing the average estimation of $-46.226M by -31.19%. Apple's SG&A was $17.26M, beating the average forecast of $7.15M by 141.32%. Lastly, the company's EPS was $-4.05, beating the average prediction of $-3.125 by 29.60%. In terms of the last quarterly report (Dec 2022), Abeona Therapeutics's revenue was $68K, missing the average analysts' forecast of $1M by -93.20%. The company's EBITDA was $-10.372M, beating the average prediction of $-600K by 1628.67%. Abeona Therapeutics's net income was $6.42M, missing the average estimation of $-36.061M by -117.79%. The company's SG&A was $5.68M, missing the average forecast of $5.72M by -0.70%. Lastly, the company's EPS was $0.82, missing the average prediction of $-0.75 by -209.33%